Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 2/3 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Myeloproliferative Disorders 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1Carcinoma, Hepatocellular 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Radiosurgery 24lenvatinib 19Radiofrequency Ablation 16Hepatectomy 13Sorafenib 12Surgical Procedures, Operative 9Radiotherapy 9camrelizumab 7Magnetic Resonance Spectroscopy 7Blood Specimen Collection 7Bevacizumab 7sintilimab 6apatinib 6Immune Checkpoint Inhibitors 6Electroporation 6atezolizumab 5tislelizumab 4Yttrium-90 4Proton Therapy 4Oxaliplatin 4Liver Transplantation 4Doxorubicin 4Control Groups 4Cisplatin 4Chemoembolization, Therapeutic 4Catheter Ablation 4spartalizumab 3entecavir 3X-Rays 3Standard of Care 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Carcinoma, Hepatocellular × Idarubicin × Clear all
NCT05053386 2021-09-22

Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma

Zhejiang Cancer Hospital

Phase NA Unknown
186 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡